BioPharma Dive September 30, 2024
The company now has more than $300 million in cash at its disposal, which it plans to use to test alpha radiopharmaceuticals against solid tumors.
Boston-based Aktis Oncology has raised $175 million in fresh funding to advance its pipeline of radiopharmaceutical medicines for cancer.
The Series B round, announced by Aktis Monday, was led by RA Capital Management and co-led by RTW Investments and Janus Henderson Investors. It also drew in pharmas that had previously backed Aktis, namely Bristol Myers Squibb, Eli Lilly and Merck & Co., the latter of which invested via its MRL Ventures Fund.
Alongside the funding, Aktis disclosed that it will share data on its research progress at the upcoming EORTC-NCI-AACR Symposium on Molecular Targets and...
Today's Sponsors
Today's Sponsor